Neuland Laboratories (NEULANDLAB) | Stock Overview & Key Data
Neuland Laboratories Performance Comparison
Stock Range
Today's Range
Low: ₹14,736.00
High: ₹15,060.00
on September 25, 2025
52 Week Range
Low: ₹10,190.70
High: ₹18,100.00
on March 3, 2025
on December 4, 2024
All-Time High: ₹18,100.00 on December 2, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR193.8B
EPS
137.75
P/E Ratio (TTM)
109.62
Forward P/E
39.91
P/B Ratio
12.71
PEG Ratio
-1.28
Div. Yield
0.08%
ROE
17.06%
Beta
0.013
Debt to Equity
10.31
Financial Highlights
Profitability
Gross Margin
47.77%
Operating Margin
4.88%
Profit Margin
13.24%
Returns and Earnings
Return on Assets (TTM)
11.93%
Return on Equity (TTM)
17.06%
EBITDA
INR3.1B
Net Income (TTM)
INR1.8B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR1,036.63
Quarterly Revenue Growth (YoY)
-33.40%
Quarterly Earnings Growth (YoY)
-85.80%
Dividend Information
Last 12-Month Dividend
₹12.00
Current Dividend Yield
0.08%
3-Year Average Dividend Yield
0.20%
3-Year Average Annual Dividend
₹12.00
3-Year Total Dividends
₹36.00
Ex-Dividend Date
July 18, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Neuland Laboratories NEULANDLAB | 193.78B Mid-cap | -7.01% | 11.06% | 22.65% | 26.15% | 5.10% | 17.45% | 1,001.92% | 1,175.35% |
| Sun Pharmaceutical SUNPHARMA | 3.94T Large-cap | 0.43% | -1.79% | -2.08% | -8.84% | -13.91% | -16.50% | 71.52% | 220.99% |
| Divi's Laboratories DIVISLAB | 1.63T Large-cap | -1.12% | -4.23% | -8.86% | 1.24% | -1.47% | 9.64% | 61.50% | 95.24% |
| Alembic APLLTD | 186.95B Mid-cap | -5.92% | -5.91% | -2.82% | -4.06% | -12.28% | -22.99% | 52.19% | -0.70% |
| Jubilant Pharmova JUBLPHARMA | 172.34B Mid-cap | -2.75% | 0.29% | -3.56% | 20.78% | 0.04% | -7.64% | 221.57% | 96.04% |
| Caplin Point CAPLIPOINT | 171.42B Mid-cap | -2.96% | 4.57% | 9.95% | 10.22% | -10.00% | 18.23% | 203.75% | 306.34% |
Ownership & Short Interest
Insider Ownership
37.77%
Institutional Ownership
25.42%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
74K
Average 90-Day Volume
53K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is NEULANDLAB's 52-week high and low?
- In the last 52 weeks, Neuland Laboratories reached a high of ₹18,100.00 (on December 4, 2024) and a low of ₹10,190.70 (on March 3, 2025).
- What is the market cap and P/E ratio for NEULANDLAB?
- Curious about Neuland Laboratories's size and valuation? Its market capitalization stands at 193.78B. When it comes to valuation, the P/E ratio (trailing twelve months) is 109.62, and the forward P/E (looking ahead) is 39.91.
- Does NEULANDLAB pay dividends? If so, what's the yield?
- Yes, Neuland Laboratories is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.08%, and the company has paid an average of ₹12.00 per share annually over the past 3 years.
- Who are Neuland Laboratories's main competitors or similar companies to consider before investing?
When looking at Neuland Laboratories, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.94T Healthcare Drug Manufacturers - Specialty & Generic -16.50% 71.52% Divi's Laboratories
DIVISLAB1.63T Healthcare Drug Manufacturers - Specialty & Generic 9.64% 61.50% Alembic
APLLTD186.95B Healthcare Drug Manufacturers - Specialty & Generic -22.99% 52.19% Jubilant Pharmova
JUBLPHARMA172.34B Healthcare Drug Manufacturers - Specialty & Generic -7.64% 221.57% Caplin Point
CAPLIPOINT171.42B Healthcare Drug Manufacturers - Specialty & Generic 18.23% 203.75% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Neuland Laboratories Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Neuland Laboratories's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 17.06%, the Debt to Equity ratio from the most recent quarter is 10.31, and its Gross Profit Margin stands at 47.77%.
- What is the recent revenue and earnings growth for NEULANDLAB?
- Looking at Neuland Laboratories's growth, its revenue over the trailing twelve months (TTM) was INR13B. Compared to the same quarter last year (YoY), quarterly revenue grew by -33.40%, and quarterly earnings saw a YoY growth of -85.80%.
- How much of NEULANDLAB stock is held by insiders and institutions?
- Wondering who owns Neuland Laboratories stock? Company insiders (like executives and directors) hold about 37.77% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 25.42%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.